Clin2
NCT06817889Possibly a fitRecruiting

Remdesivir for RSV in people with weak immune systems

Hematopoietic and Lymphatic System NeoplasmAutoimmune DiseaseRespiratory Syncytial Virus Infection

Treatments studied

Part of Immune system & allergy, Infections clinical trials.

This trial tests if remdesivir can safely treat RSV (a respiratory virus) in people with weakened immune systems, such as those who have had a stem cell or bone marrow transplant, CAR T-cell therapy, or are being treated for blood cancer. If you have a confirmed RSV infection in your nose or throat and are at moderate or high risk for complications, you may be able to join.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have tested positive for RSV using a nose or throat swab in the last 5 days.
  • You have new or worsening cold-like symptoms (like runny nose, cough, or congestion) from RSV.
  • You have had a stem cell or bone marrow transplant, CAR T-cell therapy, or bispecific antibody treatment in the past year, or are currently being treated for a blood cancer that has returned or not responded to treatment.
  • You are at moderate or high risk for severe RSV based on your age, recent treatments, and blood counts.
  • Your oxygen level is 93% or higher on room air at rest.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07402512Recruiting· Phase 3
Study of deuremidevir for RSV in infants and young children

This trial is testing a new medicine called deuremidevir for babies and young children with RSV infection. It is for those who have symptoms like fast breathing and wheezing, and have been sick for no more than 96 hours.

Xiamen, Fujian
NCT07214571Recruiting· Phase 2
Study of S-337395 for RSV in high-risk adults

This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.

Los Angeles, California
NCT07717840Recruiting· Phase 1/Phase 2
RSV vaccine study for adults 60 and older

This trial tests a new RSV vaccine in adults aged 60 and older to see if it is safe and helps the immune system fight RSV. If you are generally healthy or have stable medical conditions without recent infections or vaccines, you may be eligible.

Long Beach, California
NCT06665100Recruiting· Phase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients

This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.

Duarte, California
NCT06873633Recruiting· Phase 2
Testing remdesivir for RSV in hospitalized children under 2

This trial tests if remdesivir (Veklury) is safe and helps clear RSV in babies and toddlers who are hospitalized. It may help your child recover faster from severe RSV symptoms.

Bangkok
NCT07050732Recruiting· Phase 2
Testing RSV vaccine in people with weakened immune systems

This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.

Baltimore, Maryland

Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.